Nicholas J. Drakulich, the Founding Partner of THE DRAKULICH FIRM, APLC, has been named to the Plaintiffs' Steering Committee in the Actos (Pioglitazone) Products Liability Litigation (MDL 2299) currently underway in U.S. District Court for the Western District of Louisiana. Mr. Drakulich was appointed by the Honorable Rebecca F. Doherty in an order dated April 13, 2012. Lawsuits pending in the litigation allege that patients who ingested Actos for more than a year are at increased risks for developing bladder cancer. Plaintiffs further allege that Takeda Pharmaceuticals and other Defendants promoted Actos as a safe and effective treatment for Type II diabetes, even though they knew or should have known that taking Actos for longer than 12 months increased the risk of bladder cancer and had other serious side effects.
"I’m honored to have been selected as a member of the Actos PSC and to represent people who allege to have been seriously harmed by this medication," Nicholas (“Nick”) Drakulich said. The team of Actos litigation attorneys will work to prove that the Defendants failed to adequately warn people of the full spectrum of the drug’s side effects, including bladder cancer.
For more information about The Drakulich Firm, APLC, the International Society of Primerus Law Firms.